| Name | Title | Contact Details |
|---|---|---|
Gustavo Bonany |
Chief Technology Officer | Profile |
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
The Y: Were for youth development, healthy living, and social responsibility
Complementary Healthcare Plans is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Partners, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Health Partners, Inc. is based in Philadelphia, PA. You can find more information on Health Partners, Inc. at www.healthpart.com
St. Peter's Health Care Services is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.